

## Krystal Biotech Pipeline

	Product	Protein	Indication	Discovery	Preclinical	Phase 1/2	Phase 3	Commercial
Dermatology	<b>B-VEC</b> <sup>†‡•Δ‡§</sup>	Type VII collagen	Dystrophic Epidermolysis Bullosa	→				FDA-Approved on May 19, 2023
	<b>KB105</b> <sup>†‡•‡</sup>	Transglutaminase 1 (TGM1)	TGM1-deficient ARCI	→				
	<b>KB104</b> <sup>‡</sup>	Serine Peptidase Inhibitor Kazal Type 5 (SPINK5)	Netherton Syndrome	→				
	<b>KB1XX</b>	Undisclosed Programs		→				
Respiratory	<b>KB5XX</b>	Vector Encoded Antibodies	Chronic Skin Conditions	→				
	<b>KB407</b> <sup>†‡‡</sup>	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)	Cystic Fibrosis	→				
	<b>KB408</b>	Alpha-1 antitrypsin (AATD)	alpha-1 antitrypsin deficiency	→				
	<b>KB4XX</b>	Undisclosed Programs		→				

All pipeline compounds are investigational. All pipeline compounds are wholly owned.

†: FDA Orphan Drug Designation

‡: FDA Rare Pediatric Disease Designation

•: Fast-track Designation

Δ: FDA RMAT designation

‡: EMA Orphan Drug Designation

§: EMA PRIME Designation

Rare disease

More prevalent conditions

## Jeune Aesthetics Pipeline

	Product	Gene	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Commercial
Aesthetics	<b>KB301</b>	Type III collagen	TBD	→					
	<b>KB302</b>	Type I collagen	TBD	→					
	<b>KB303</b>	Elastin	TBD	→					
	<b>KB304</b>	Type III collagen & Elastin	TBD	→					
	<b>KB305</b>	Type IV collagen	TBD	→					

All pipeline compounds are investigational, being evaluated in clinical or pre-clinical studies. All pipeline compounds are wholly owned.